Comparative predictive value of immunotherapy biomarkers: a systematic review and network meta-analysis

Biomarker performance varies by cancer type and clinical context. ctDNA, PD-L1 (high thresholds, as ≥50%), and TMB are leading predictors, with combinations potentially optimizing performance. Future research must address heterogeneity and standardization to refine individualized immunotherapy strategies.